<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000559256"><TermName>lestaurtinib</TermName><TermPronunciation>(leh-STOR-tih-nib)</TermPronunciation><TermDefinition><DefinitionText>A drug being studied in the treatment of acute leukemias and some other types of cancer. It binds to a protein that is present on the surface of some types of cancer cells and stops them from dividing. Lestaurtinib is a type of receptor tyrosine kinase inhibitor and a type of indolocarbazole alkaloid. Also called CEP-701.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000720479" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;lestaurtinib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000720478" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;lestaurtinib&quot;" language="es" id="_4"/><SpanishTermName>lestaurtinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento en estudio para el tratamiento de las leucemias agudas y algunos otros tipos de cáncer. Se une a una proteína que está presente en la superficie de algunos tipos de células cancerosas y les impide que se multipliquen. El lestaurtinib es un tipo de inhibidor de la tirosina cinasa y un tipo del alcaloide indolocarbazole. También se llama CEP-701.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2007-11-30</DateFirstPublished><DateLastModified>2008-03-10</DateLastModified></GlossaryTerm>
